High risk of anal and rectal cancer in patients with anal and/or perianal Crohn’s disease.
Clin Gastroenterol Hepatol. 2017 Nov 30;:
Authors: Beaugerie L, Carrat F, Nahon S, Zeitoun JD, Sabate JM, Peyrin-Biroulet L, Colombel JF, Allez M, Fléjou JF, Kirchgesner J, Svrcek M, CESAME Study Group
BACKGROUND AND AIMS: Little is known about the magnitude of the risk of anal and rectal cancer in patients with anal and/or perineal Crohn’s disease. We aimed to assess the risk of anal and rectal cancer in patients with Crohn’s perianal disease followed in the Cancers Et Surrisque Associé aux Maladies inflammatoires intestinales En France (CESAME) cohort.
METHODS: We collected data from 19,486 patients with Inflammatory Bowel Disease (IBD) enrolled in the observational CESAME study in France, from May 2004 through June 2005; 14.9% of participants had past or current anal and/or perianal Crohn’s disease. Subjects were followed for a median time of 35 months (interquartile range, 29-40 months). To identify risk factors for anal cancer in the total CESAME population, we performed a case-control study in which participants were matched for age and sex.
RESULTS: Among the total IBD population, 8 patients developed anal cancer and 14 patients developed rectal cancer. In the subgroup of 2911 patients with past or current anal and/or perianal Crohn’s lesions at cohort entry, 2 developed anal squamous-cell carcinoma, 3 developed perianal fistula-related adenocarcinoma, and 6 developed rectal cancer. The corresponding incidence rates were 0.26/1000 patient-years for anal squamous-cell carcinoma, 0.38/1000 patient-years for perianal fistula-related adenocarcinoma, and 0.77/1000 patient-years for rectal cancer. Among the 16,575 patients with ulcerative colitis or Crohn’s disease without anal or perianal lesions, the incidence rate of anal cancer were 0.08/1000 patient-years and of rectal cancer was 0.21/1000 patient-years. Among factors tested by univariate conditional regression (IBD subtype, disease duration, exposure to immune-suppressive therapy, presence of past or current anal and/or perianal lesions), the presence of past or current anal and/or perianal lesions at cohort entry was the only factor significantly associated with development of anal cancer (odds ratio, 11.2; 95%CI, 1.18-551.51) (P = .03).
CONCLUSION: In an analysis of data from the CESAME cohort in France, patients with anal and/or perianal Crohn’s disease have a high risk of anal cancer, including perianal fistula-related cancer, and a high risk of rectal cancer.
PMID: 29199142 [PubMed – as supplied by publisher]